<DOC>
	<DOCNO>NCT01408316</DOCNO>
	<brief_summary>This two part study design evaluate PK profile PX-866 capsule versus tablet , evaluate effect food PK PX-866 tablet healthy volunteer .</brief_summary>
	<brief_title>Study Pharmacokinetics Pharmacodynamics Crystalline PX-866 Tablets Amorphous PX-866 Capsules Healthy Volunteers</brief_title>
	<detailed_description>This two part , Phase 1 , open label , cross study design evaluate PK profile crystalline PX-866 tablet relative amorphous PX-866 capsule evaluate effect administration food PK crystalline PX-866 tablet healthy volunteer .</detailed_description>
	<criteria>Between 18 65 year age ( inclusive Able communicate well study staff read , understand , sign date write informed consent form ( ICF ) study . Must willing use double barrier contraception 90 day last dose study drug . If female child bear potential , volunteer must negative serum pregnancy test screen Day 1 Day 1 . Body mass index ( BMI ) 18 32 kg/m2 ( inclusive ) screening . Judged investigator good health purpose study , base result medical history , physical examination , ECG laboratory test show major clinically significant finding pre dose Day 1 . Has normal hepatobiliary enzyme bilirubin ( total conjugate ) result Day 1 and/or Day 1 . Has normal hemoglobin , hematocrit , absolute neutrophil count , absolute lymphocyte count platelet count Day 1 Day 1 . Blood pressure 95 140 mm Hg ( inclusive ) systolic , 50 90 mm Hg ( inclusive ) diastolic , pulse rate ( determine vital sign measurement ) 40 100 beat per minute ( inclusive ) screen pre dose Day 1 . Ability intent comply requirement study . Signed ICF prior conduct study procedure . History illness condition , opinion investigator , may compromise integrity study data pose significant risk administer study drug subject . This may include limited history relevant drug allergy ; history cardiovascular central nervous system disease ; history presence clinically significant pathology ; history mental illness . Use prescription medication ( systemic exposure ) within 14 day prior Day 1 , likelihood needing use medication course study participation . Use counter product systemic exposure ( e.g. , oral medication , herbal preparation , dietary supplement except acetaminophen less two gm per day vitamin supplement near recommended daily allowance ) within 7 day prior Day 1 , likelihood needing use product course study participation . Use known inhibitor inducer CYP3A4 , ( e.g. , St. John 's Wort , ginkgo biloba , garlic supplement , grapefruit grapefruit juice , apple juice , orange juice ) within 7 day prior Day 1 . Typically consume two unit alcoholic beverage per day 14 unit per week ( one unit alcohol one pint [ 568 mL ] beer lager , one glass [ 125 mL ] wine , one 25 mL shoot 40 % spirit ) . Has consume alcohol within 72 hour prior dose Day 1 . Typically consume five 8 ounce serving per day coffee , cola , caffeinated beverage product similar amount caffeine . Has consume caffeinated beverage product within 48 hour prior Day 1 dosing . Has history drug alcohol abuse addiction ( DSM IV criterion ) within 2 year prior Day 1 . Has use tobacco nicotine contain product within 6 month prior Day 1 . Has positive urine drug screen opiate , methadone , cannabinoids , cocaine , amphetamines/methamphetamines , barbiturate , benzodiazepine , cotinine alcohol screen visit Day 1 . Has participate clinical study involve administration either investigational marketed drug within 30 day 5 half life ( whichever longer ) prior Day 1 . Has dose PX 866 previously . Has donate blood significant loss blood within 56 day prior Day 1 donate one unit plasma within 7 day prior Day 1 . Has positive result screen hepatitis B antigen , hepatitis C virus antibody , human immunodeficiency virus 1 antibody human immunodeficiency virus 2 antibody . Has illness within 5 day prior Day 1 . Is female pregnant , nursing , plan become pregnant study within 90 day last dose study drug . Has history gall bladder disease , bowel pattern â‰¥ 2 stool per day intermittent diarrhea , alteration gastrointestinal anatomy , opinion investigator , may alter absorption elimination PX 866 . Has QTcF &gt; 450 msec ECG prior Day 1 dose . In estimation investigator , volunteer significant number premature atrial ventricular premature beat significant ECG finding , see continuous ECG data acquire admission enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Healthy Volunteer</keyword>
	<keyword>PX-866</keyword>
	<keyword>PI3K Inhibitor</keyword>
</DOC>